Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | EDNRA | P25101 | 3/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8828117 | 1.00 | KMT2A (0.55) | KMT2AMEN1RAB9AEDNRAMAPK9 | |
| SCHEMBL15238894 | 1.00 | KMT2A (0.55) | KMT2AMEN1RAB9AEDNRAMAPK9 | |
| SCHEMBL4179605 | 0.92 | PTGS1 (0.51) | KMT2AMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL3144643 | 0.86 | RAB9A (0.50) | KMT2ARAB9AMAPK9KDM4EL3MBTL1 | |
| SCHEMBL8249411 | 0.86 | RAB9A (0.50) | KMT2ARAB9AMAPK9KDM4EL3MBTL1 | |
| SCHEMBL15239118 | 0.86 | RAB9A (0.50) | KMT2ARAB9AMAPK9KDM4EL3MBTL1 | |
| SCHEMBL4381742 | 0.85 | EDNRA (0.48) | KMT2AMEN1RAB9AEDNRAMAPK9 | |
| SCHEMBL2857614 | 0.85 | EDNRA (0.48) | KMT2AMEN1RAB9AEDNRAMAPK9 | |
| Hydrochloric Acid SCHEMBL4585660 | 0.85 | RAB9A (0.49) | KMT2ARAB9AMAPK9KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL131112 | 0.85 | RAB9A (0.49) | KMT2ARAB9AMAPK9KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1529042-B1 | ARYLAMIDES | INTERMED DISCOVERY GMBH (DE) | 2013-02-20 | — | — | EP | disclosed |
| EP-1988078-B1 | Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders | ORTHO MCNEIL PHARM INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20090149528-A1 | Cinnamic acid amides | BAYER HEALTHCARE AG (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149528-A1 | Cinnamic acid amides | BAYER HEALTHCARE AG (DE) | 2009-06-11 | — | — | US | disclosed |
| EP-1988078-A1 | Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders | Ortho-McNeil Pharmaceutical, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-7402683-B2 | 3-(1,3-benzodioxol-5-yl)-N-{(1S)-3-[((1S)-2-methyl-1-{[(3R,4S)-4-methyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}propyl)amino]-3-oxo-1-phenylpropyl}-2-propenamide; bactericide, bacterial infection; septic infections, bone and joint infections, skin infections; veterinary medicine | BAYER HEALTHCARE AG (DE) | 2008-07-22 | — | — | US | disclosed |
| US-7402683-B2 | 3-(1,3-benzodioxol-5-yl)-N-{(1S)-3-[((1S)-2-methyl-1-{[(3R,4S)-4-methyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}propyl)amino]-3-oxo-1-phenylpropyl}-2-propenamide; bactericide, bacterial infection; septic infections, bone and joint infections, skin infections; veterinary medicine | BAYER HEALTHCARE AG (DE) | 2008-07-22 | — | — | US | disclosed |
| US-7348357-B2 | bactericide; derivatives of pseudopeptide Andrimid in which beta-phenylalanine amide is replaced by heteroaromatic or substituted aromatic amide; N-{(1S)-3-[((1S)-1-{[(3R,4S)-1,4-Dimethyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}-2-methylpropyl)amino]-3-oxo-1-phenylpropyl}-2-pyridinecarboxamide; antibiotics | BAYER HEALTHCARE AG (DE) | 2008-03-25 | — | — | US | disclosed |
| US-7348357-B2 | bactericide; derivatives of pseudopeptide Andrimid in which beta-phenylalanine amide is replaced by heteroaromatic or substituted aromatic amide; N-{(1S)-3-[((1S)-1-{[(3R,4S)-1,4-Dimethyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}-2-methylpropyl)amino]-3-oxo-1-phenylpropyl}-2-pyridinecarboxamide; antibiotics | BAYER HEALTHCARE AG (DE) | 2008-03-25 | — | — | US | disclosed |
| EP-0923555-B1 | CARBOXAMIDE DERIVATIVES OF PYRROLIDINE, PIPERIDINE AND HEXAHYDROAZEPINE FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20020019402-A1 | Integrin inhibitors and their methods of use | AMGEN INC. | 2002-02-14 | — | — | US | disclosed |
| US-6344570-B1 | ANTISTICKING AGENTS FOR CELLS | ASTRAZENECA UK LIMITED (GB) | 2002-02-05 | — | — | US | disclosed |
| EP-1133484-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | AstraZeneca AB (SE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2001044230-A1 | 1-(AMINOPHENYL)-2-PYRROLIDONES AS INTEGRIN INHIBITORS | AMGEN INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-1030835-A2 | UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-30 | — | — | EP | disclosed |
| US-6069254-A | Carboxamide derivatives of piperidine for the treatment of thrombosis disorders | ORTHO PHARMACEUTICAL CORP. (US) | 2000-05-30 | — | — | US | disclosed |
| WO-2000005223-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-03 | — | — | WO | disclosed |
| EP-0923555-A1 | CARBOXAMIDE DERIVATIVES OF PYRROLIDINE, PIPERIDINE AND HEXAHYDROAZEPINE FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1999024398-A2 | UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
| WO-1997041102-A1 | CARBOXAMIDE DERIVATIVES OF PYRROLIDINE, PIPERIDINE AND HEXAHYDROAZEPINE FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019402-A1 | Integrin inhibitors and their methods of use | ITGB3, ITGA5, ITGB5 | KMT2A 3746/4885MEN1 3266/4885RAB9A 1232/4885 |
| US-20090149528-A1 | Cinnamic acid amides | PIGS, NISCH, PIGO | KMT2A 2826/4885MEN1 2220/4885RAB9A 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.